Pamorelin (Triptorelin)

Pamorelin is a GnRH‑agonist that modulates the hypothalamic‑pituitary‑gonadal axis in several hormone‑dependent conditions.

• Prostate cancer: provides sustained suppression of testosterone to slow tumor progression.
• Endometriosis: reduces estrogen production to alleviate pelvic pain and lesion growth.
• Assisted reproduction: controls ovarian stimulation cycles by preventing premature luteinizing hormone surges.
• Uterine fibroids: lowers estrogen levels to shrink fibroid size and reduce bleeding.
• Precocious puberty: delays onset of secondary sexual characteristics in affected children.

• Triptorelin is a synthetic analogue of gonadotropin‑releasing hormone that binds with high affinity to pituitary GnRH receptors. Continuous exposure desensitizes the receptor, leading to down‑regulation of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) release, which in turn suppresses downstream sex‑steroid production (testosterone and estradiol).

Triptorelin may cause a range of adverse reactions, most of which are dose‑dependent and transient.

Common Side Effects

• Hot flashes
• Injection site pain or erythema
• Headache
• Fatigue
• Nausea
• Decreased libido

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis)
• Cardiovascular events such as myocardial infarction
• Bone demineralisation leading to fractures
• Severe depression or mood changes
• Hepatic dysfunction
• Pituitary apoplexy (very rare)

When using Pamorelin, clinicians should consider several safety measures:

• Cardiovascular assessment: evaluate history of heart disease.
• Bone health monitoring: perform baseline densitometry in long‑term therapy.
• Hormonal status: check baseline testosterone/estradiol levels.
• Pregnancy avoidance: ensure effective contraception for women of childbearing age.
• Drug interactions: review concomitant medications that affect hormone metabolism.

Store at ambient temperature: keep in original packaging, protect from moisture and light.

Triptilelin interacts with several drug classes that can modify its hormonal effects.

Major Interactions (Avoid)

• Antidepressants (SSRIs) that may exacerbate mood swings.
• Strong CYP3A4 inducers: rifampicin 
• Hormone replacement therapy (estrogen‑containing )

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin) – monitor INR.
• Antidiabetic agents – watch for altered glucose control.
• Steroid S  

the   t  t  t ",